General Updates

October 12, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Update on further investment in PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary Dear Sir/ Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”), we wish to inform you that Dr. Lal PathLabs Limited (“the Company”) has made a further investment in PathLabs Unifiers Private Limited (“PUPL”), a Wholly Owned Subsidiary of the Company, by subscribing to the equity shares of PUPL on October 12, 2026. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, is enclosed herewith as “Annexure – A”. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl: as above Annexure-A DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: SN Particulars Acquisition of Company 1 Name of the target entity, details in brief PathLabs Unifiers Private Limited (“PUPL”) such as size, turnover etc. Turnover: FY 2026: 7.23 Crores FY 2025: 7.10 Crores FY 2024: 7.28 Crores 2 Whether the acquisition would fall within PUPL, being a Wholly Owned Subsidiary is a related party transaction(s) and whether related party of the Company. the promoter/ promoter group/ group companies have any interest in the The proposed investment is in the nature of entity being acquired? If yes, nature of related party transaction and will be on an interest and details thereof and whether arm’s length basis. the same is done at “arm’s length” 3 Industry to which the entity being Healthcare/ Diagnostics Services acquired belongs 4 Objects and impact of acquisition The proposed subscription of shares is (including but not limited to, disclosure intended to fund the acquisition by PUPL, of reasons for acquisition of target remaining 30% equity stake in CentraPath entity, if its business is outside the main Labs Private Limited (“CPL”), Subsidiary of line of business of the listed entity) PUPL. Post this acquisition, CPL will become Wholly Owned Subsidiary of PUPL. 5 Brief details of any governmental or Not Applicable regulatory approvals required for the acquisition 6 Indicative time period for completion of Completed the acquisition 7 Consideration - whether cash Cash Consideration consideration or share swap or any other form and details of the same 8 Cost of acquisition and/or the price at Not exceeding INR 30.3 Crores. which the shares are acquired 9 Percentage of shareholding / control PUPL shall continue to remain a Wholly acquired and / or number of shares Owned Subsidiary of the Company. acquired 10 Brief background about the entity PUPL was incorporated on December 12, acquired in terms of products/line of 2018, in National Capital Territory Delhi and is business acquired, date of engaged in business of providing Healthcare/ incorporation, history of last 3 years Diagnostics Services. turnover, country in which the acquired entity has presence and any other Turnover: As mentioned in Clause 1 above significant information (in brief)